With the help of lead investor BB Biotech Ventures, BioVascular rounded up $10.87 million in series C financing. The San Diego, CA-based company plans on using the money to complete clinical trials of its two compounds, Saratin and BVI-007. Saratin--which is currently in Phase I/II--is being developed to reduce the failure of vascular grafts due to intimal hyperplasia. BVI-007 reduces platelet production without affecting platelet function, and is being studied in a Phase Ib dose selection clinical trial.

- see BioVascular's release for more

Related Articles:
Biotech, emerging markets are big VC targets. Report
Serial investors: Comforting figures for VC backers. Report
VC adds billions in its pursuit of biotech ventures. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report